MOTS-c

Evidence

MOTS-c

Mitochondrial-Derived Peptide • Metabolic Signaling • Insulin- Sensitivity Research

At a Glance

What is MOTS-c?

MOTS-c is a naturally occurring peptide made from:

16 amino acids What makes it unusual is where its genetic instructions come from.

Most peptides are encoded by DNA in the cell nucleus.

MOTS-c comes from:

mitochondrial DNA specifically from a small region inside the mitochondrial 12S rRNA gene. FDA’s 2026 scientific review also describes MOTS-c as a naturally occurring mitochondrial peptide made of 16 amino acids. ( fda.gov) MOTS-c appears to be involved in how cells respond to:

• energy demand

• metabolic stress

• glucose availability

• exercise

• changes in mitochondrial function

Most of what we currently know about its possible treatment effects comes from:

cell and animal research rather than completed human injection trials.

How well studied is it?

Interesting science, but injected-human research is only beginning This distinction is extremely important.

MOTS-c has:

• strong laboratory research

• many animal studies

• human studies measuring the MOTS-c our bodies naturally produce

• human exercise research

• an active Phase 2a human treatment trial

But we do not yet have published results from controlled trials showing that injected native MOTS-c improves:

• insulin sensitivity

• body weight

• body composition

• energy

• endurance

• exercise performance

in humans.

FDA’s 2026 review found no published studies in which MOTS-c had been administered to humans that could establish its safety or effectiveness. FDA therefore described human safety and effectiveness as unknown. ( fda.gov) The important update is that this is now beginning to change.

A Phase 2a study is currently testing MOTS-c in adults with prediabetes and overweight or obesity. ( clinicaltrials.gov) Evidence level FDA-approved human evidence: None Completed injected-human efficacy evidence: None yet Active human clinical research: Yes, Phase 2a Human natural-MOTS-c / observational research: Moderate Animal / cell research: Strong Mechanistic research: Strong but incomplete Community injection protocols: Common but unproven

What may it help with?

Currently Being T ested in Humans

Insulin Sensitivity

The current Phase 2a MOTS-MET trial is studying adults with:

• prediabetes

• overweight or obesity

• insulin resistance

The main question is whether approximately:

12 weeks of MOTS-c treatment

can improve insulin sensitivity compared with placebo. ( clinicaltrials.gov) Important The trial has not reported results yet .

So Navaro should say:

MOTS-c is being studied for insulin sensitivity in humans.

Not:

MOTS-c has been proven to improve human insulin sensitivity .

Human Exercise Research

Human research has shown that the MOTS-c naturally produced by our bodies changes with exercise.

A 2021 study found that exercise increased endogenous MOTS-c in human skeletal muscle and circulation. ( pubmed.ncbi.nlm.nih.gov) What This Supports MOTS-c appears to be part of the body’s normal response to:

exercise and increased energy demand.

What It Does Not Prove It does not prove that injecting MOTS-c:

• recreates exercise

• improves endurance

• causes fat loss

• improves blood sugar

• increases mitochondrial function

in humans.

Strong Animal / Cell Evidence

Animal and laboratory studies suggest MOTS-c may affect:

• insulin sensitivity

• glucose metabolism

• metabolic flexibility

• obesity-related metabolism

• physical capacity

• skeletal-muscle function

• age-related metabolic changes

These findings are why researchers are now testing MOTS-c in humans.

But for Navaro they should remain clearly labeled:

Animal / cell evidence until human treatment results are available.

What has it NOT been proven to help with?

Injected MOTS-c has not yet been proven in humans to improve:

• fat loss

• obesity

• insulin resistance

• diabetes

• endurance

• athletic performance

• mitochondrial function

• fatigue

• GLP-1-related fatigue

• muscle growth

• recovery

• longevity

• anti-aging

• metabolic flexibility

• body composition

That does not mean these effects are impossible.

It means we do not yet have controlled human injection results proving them.

Human Clinical Research

Current Phase 2a T rial The active trial uses:

Route: Subcutaneous T reatment period: 12 weeks

Safety follow-up: Through approximately week 16 Estimated enrollment: About 120 adults The study is enrolling adults with prediabetes and overweight or obesity. ( clinicaltrials.gov) Important Do not publish an exact clinical milligram dose unless it is clearly disclosed by the current trial record.

This is an investigational study, not an approved treatment protocol.

Human Clinical Research

The current study uses repeated SC treatment across:

12 weeks The trial will provide important information about repeated human exposure.

(clinicaltrials.gov)

Community

Commonly:

2–3 times per week Other community schedules include:

• once weekly

• every few days

• higher-frequency short cycles

Best-supported frequency?

W e do not know yet.

No completed human trial has established the best MOTS-c dosing frequency.

Human Clinical Research

The current Phase 2a study uses:

12 weeks of treatment followed by additional safety follow-up. ( clinicaltrials.gov)

Community

Community protocols often use approximately:

4–6 weeks on followed by:

2–4 weeks off Does MOTS-c Need to Be Cycled?

W e do not know.

There is no human evidence showing that MOTS-c requires a break to:

• reset a receptor

• restore sensitivity

• prevent tolerance

A specific MOTS-c receptor has not even been clearly identified. FDA’s 2026 review specifically states that its molecular target or targets remain unknown.

(fda.gov)

Expected Results Timeline

Human Clinical Research

There Is No Injected-Human Results Timeline Y et This is one of the most important things to get right.

The first Phase 2a study is still underway.

There are no published results showing:

• insulin sensitivity improves by week 2

• fat loss starts at week 4

• endurance improves at week 6

• energy increases within days

from controlled MOTS-c injections in humans. ( clinicaltrials.gov)

What the Current Trial Is Testing

The current study is looking at metabolic outcomes after approximately:

12 weeks of treatment with safety monitoring continuing afterward. ( clinicaltrials.gov) The main focus is:

insulin sensitivity Other metabolic measurements include blood-sugar and cardiometabolic markers.

Clinical T akeaway The first real injected-human results timeline is still being established.

Community-Reported Timeline

Community material describes changes over roughly:

several days to several weeks with energy or exercise-related changes often discussed during:

4–6 week community cycles Important This is:

community-reported not:

clinically proven Best Production W ording Community-reported: some users describe changes in energy or exercise tolerance over the first several weeks. These reports have not yet been confirmed in controlled human MOTS-c injection trials.

Simple Timeline for the T op Card Clinical: No injected-human results timeline exists yet. The current Phase 2a trial is testing metabolic outcomes over approximately 12 weeks .

Community-reported: subjective energy or exercise-related changes are described over several weeks , but these reports remain anecdotal.

What Should NOT Be Called Established MOTS-c Side

Effects?

The current live page lists things such as:

• hypoglycemia

• fatigue

• flushing

• GI symptoms

• headache

• flu-like symptoms

• “AMPK overstimulation”

as though their frequency in humans is known.

It is not.

These should instead be classified as:

Community-reported or theoretical until proper human safety results are available.

Hypoglycemia

The current live page describes low blood sugar as the major practical side effect and says MOTS-c should always be used before exercise.

There is not enough human evidence to support that statement.

MOTS-c is being studied because it may affect insulin sensitivity and glucose metabolism.

So changes in glucose control are biologically worth watching.

But:

Low blood sugar has not been established as the main adverse effect of injected MOTS-c in humans.

V erdict Possible in theory , but unconfirmed in humans

Injection-Site Reactions

Community users report things such as:

• redness

• soreness

• irritation

But no completed human MOTS-c trial currently tells us how often these happen.

V erdict Community-reported; true rate unknown

Regulatory Status at a Glance

FDA approved?

No Neither MOTS-c free base nor MOTS-c acetate is part of an FDA-approved drug. ( fda.gov) Human clinical development?

Y es A Phase 2a trial is currently underway in adults with prediabetes and overweight or obesity. ( clinicaltrials.gov)

U.S. Compounding Status

FDA evaluated:

• MOTS-c free base

• MOTS-c acetate

for possible inclusion on the 503A Bulks List.

FDA staff concluded that the available evidence weighed against inclusion , citing lack of established human safety/effectiveness and concerns about product characterization and immunogenicity. ( fda.gov) Important An advisory committee review is not the same thing as final FDA approval of a compounded drug .

Best W ording Not FDA approved. MOTS-c free base and acetate underwent FDA compounding review in 2026. FDA staff concluded that the available evidence weighed against inclusion on the 503A Bulks List.

W ADA Status

Prohibited MOTS-c appears on the 2026 W ADA Prohibited List under AMPK activators. ( wada-ama.org) Athletes who are subject to W ADA rules should treat this as an important anti-doping issue.

Bottom Line

MOTS-c has interesting mitochondrial science, but human injection research is still at a very early stage.

What we know reasonably well:

• MOTS-c is a real 16-amino-acid peptide

• its genetic instructions come from mitochondrial DNA

• it participates in metabolic signaling

• the MOTS-c our bodies naturally produce changes with exercise

• animal studies show potentially important metabolic effects

• human treatment research is now underway. ( fda.gov)

What we do not yet know from completed human injection trials :

• the best dose

• the best frequency

• the best time of day

• human injection half-life

• whether it improves insulin sensitivity

• whether it improves endurance

• whether it causes fat loss

• whether it improves fatigue

• actual human side-effect rates

• whether cycling is useful

Community protocols commonly use:

5–10 mg several times per week, often around exercise.

Those should be displayed as:

community protocols not:

clinical dosing

Quick Logic Summary

Protocol Question Verdict Is MOTS-c a real mitochondrial-derived peptide? Y es Is it 16 amino acids long? Y es Does its sequence come from mitochondrial DNA? Y es Is AMPK involved? Strong animal/cell evidence Is AMPK the MOTS-c receptor? No Does natural MOTS-c respond to human exercise? Y es Has injected MOTS-c proven human efficacy? Not yet Is a human Phase 2a trial underway? Y es Is SC administration being studied? Y es 5–10 mg several times weekly? Community protocol

Protocol Question Verdict 200 mcg → 1 mg titration? No human trial support Pre-workout required? No Fasted dosing required? No evidence Morning required? No evidence 4–6 week cycle? Community convention 2–4 week reset? No proven reason Human injection half-life known? No Human side-effect rates known? No FDA approved? No W ADA prohibited? Y es

What Does MOTS-c Actually Target?

The current live page says:

T arget: AMPK That is too simple.

MOTS-c does not have one clearly identified receptor like:

• liraglutide → GLP-1 receptor

• Tesamorelin → GHRH receptor

Instead, laboratory research suggests MOTS-c affects several parts of cellular metabolism.

These include:

• folate metabolism

• purine metabolism

• AICAR

• AMPK-related signaling

• stress-response genes

Under metabolic stress, MOTS-c can also move into the nucleus and affect gene activity.

FDA’s 2026 review specifically says the molecular target or targets through which MOTS-c works remain unknown. ( fda.gov) Simple V ersion MOTS-c appears to help cells respond to metabolic stress and changing energy demands.

AMPK seems to be part of that response.

But:

AMPK is not an identified “MOTS-c receptor. ” V erdict W e understand parts of the pathway , but the exact target is still unknown.

Human Half-Life

Unknown There is no established published half-life for native injected MOTS-c in humans.

So the page should not claim:

• it lasts a certain number of hours

• it needs to be redosed based on that number

• one dose provides a certain number of days of signaling

V erdict W e do not know yet.

How Long Do the Effects Last?

Also unknown in injected humans.

It is possible that a short period of peptide exposure could trigger longer-lasting metabolic changes.

But this has not been measured well enough in humans to give a reliable duration.

V erdict Possible, but not measured in humans yet.

Does It Build Up With Repeated Use?

We do not yet have published human injection data showing:

• how much MOTS-c builds up

• whether it reaches steady levels

• how quickly it washes out

• how long it stays in tissues

V erdict Unknown

Does the Route Match the Research?

Current Human T rial SC FDA Compounding Nomination SC Community SC or IM

V erdict SC currently has the strongest human-research precedent.

But that means:

SC is being studied not:

SC efficacy has been proven.

Important Research Note

Four different types of MOTS-c evidence are often mixed together online.

1. Natural Human MOTS-c

Humans naturally produce MOTS-c.

Exercise studies show that these natural levels change with physical activity.

(pubmed.ncbi.nlm.nih.gov) That is:

real human evidence but it is not evidence from MOTS-c injections .

2. Animal and Cell Research

This is where many of the exciting claims come from.

Animal and laboratory studies have investigated:

• insulin sensitivity

• glucose metabolism

• obesity

• endurance

• physical function

• aging-related changes

These studies are important.

But:

mouse results are not human treatment results.

3. Current Human Phase 2a Research

MOTS-c is now being tested as an actual treatment in humans.

The current study is enrolling approximately:

120 adults with:

• prediabetes

• overweight or obesity

and is testing MOTS-c against placebo for approximately:

12 weeks with continued safety follow-up. ( clinicaltrials.gov)

Status Ongoing / no published efficacy results yet

Research at a Glance

FDA-Approved Human Evidence

None MOTS-c is not FDA approved. ( fda.gov)

Human Treatment Evidence

Beginning A Phase 2a trial is underway.

No treatment results are available yet. ( clinicaltrials.gov)

Human Natural / Observational Evidence

Moderate Human research supports:

• natural MOTS-c production

• exercise-related changes

• relationships with metabolic and physical characteristics

Animal / Cell Evidence

Strong This is where most treatment claims currently come from.

Mechanistic Evidence

Moderate to Strong We know several pathways MOTS-c appears to affect.

We do not yet know its exact receptor or molecular target. FDA specifically highlighted this uncertainty in 2026. ( fda.gov)

Community / Anecdotal Evidence

Common but Low Quality Useful for showing how people currently use MOTS-c.

Not enough to establish safety or effectiveness.

Overview

MOTS-c is one of the more unusual compounds in the library.

It is a:

mitochondrial-derived peptide whose genetic instructions come from mitochondrial DNA. ( fda.gov) Research suggests that MOTS-c helps cells respond to changes in:

• energy demand

• glucose

• metabolic stress

Animal and cell studies suggest effects involving:

• insulin sensitivity

• glucose metabolism

• AMPK-related signaling

• metabolic adaptation

Human studies also show that the MOTS-c our bodies naturally make changes with exercise. ( pubmed.ncbi.nlm.nih.gov) The big unanswered question is:

Does injecting MOTS-c create useful metabolic effects in people?

The current Phase 2a trial is finally beginning to test that directly. ( clinicaltrials.gov)

Evidence Strength

Overall Evidence Rating

Strong preclinical science, very early injected-human evidence Strong Evidence F or

• MOTS-c exists naturally

• 16-amino-acid structure

• mitochondrial DNA origin

• involvement in metabolic signaling

• natural MOTS-c changes with exercise

• metabolic effects in animal and cell models

Currently Being T ested in Humans

• insulin sensitivity

• glucose-related markers

• body weight

• waist circumference

• safety of repeated SC treatment. ( clinicaltrials.gov)

Not Established in Injected Humans

• fat loss

• endurance

• energy improvement

• GLP-1 fatigue relief

• anti-aging

• longevity

• best dose

• best frequency

• best timing

• injection half-life

• need for cycling

• true adverse-effect rates

Category

Mitochondrial-Derived Peptides / Metabolic Signaling

Compound

MOTS-c Full name:

Mitochondrial Open Reading F rame of the 12S rRNA Type-C

Compound Type

16-amino-acid mitochondrial-derived peptide MOTS-c is:

• peptide-based

• encoded by mitochondrial DNA

• involved in metabolic signaling

It is not:

• a stimulant

• a GLP-1 agonist

• insulin

• growth hormone

• a conventional drug with one clearly identified receptor

Primary Research Focus

Current Human Trial Focus

• insulin sensitivity

• prediabetes

• overweight / obesity

• metabolic health

Animal / Cell Research Focus

• glucose metabolism

• metabolic flexibility

• skeletal-muscle metabolism

• obesity

• physical capacity

• aging-related metabolic changes

Not Established

• bodybuilding

• athletic enhancement

• fat-loss treatment

• fatigue treatment

• longevity treatment

• anti-aging treatment

How It Works / Mechanism

MOTS-c appears to help cells respond to metabolic stress.

Simple V ersion When a cell’s energy needs change, MOTS-c appears to help send signals that tell the cell:

adjust how you use fuel and respond to the stress.

Research suggests MOTS-c can affect pathways involving:

folate metabolism → AICAR → AMPK-related signaling MOTS-c can also move into the nucleus during metabolic stress and influence gene activity.

Important Do not simplify this to:

“MOTS-c binds to the AMPK receptor. ” AMPK is not the known MOTS-c receptor.

FDA’s review says MOTS-c’s molecular target remains unknown. ( fda.gov)

Human Clinical Research

Current Phase 2a Route: SC T reatment duration: 12 weeks Exact clinical dose information should be copied directly from the trial record if and when it is publicly disclosed clearly.

FDA Compounding Nomination

Products were proposed at:

5 mg and:

10 mg SC. ( fda.gov) Important These are:

proposed compounded doses not:

FDA-approved doses

Research Community

Community protocols commonly describe:

5–10 mg several times per week.

Human Research

Repeated SC treatment is currently being studied.

Community

Often:

2–3 times per week with many other schedules also discussed.

Evidence Assessment We do not have completed human research telling us which schedule works best.

Possible Benefits

Human Evidence

Natural Exercise Response The MOTS-c produced naturally by the human body increases with exercise.

(pubmed.ncbi.nlm.nih.gov) Metabolic Associations Human observational studies have found relationships between MOTS-c and metabolic characteristics.

These findings are interesting.

They do not prove injections are beneficial.

Animal / Cell Evidence

Insulin Sensitivity Animal research suggests MOTS-c can improve insulin sensitivity.

Glucose Metabolism Preclinical studies show changes in glucose handling.

Metabolic Health Foundational research found important metabolic effects in animal models.

Exercise / Physical Capacity Animal studies have reported improved physical capacity.

Important These remain:

animal or laboratory treatment effects until human injection trials confirm them.

What It Does Not Help With, Based on Current

Evidence

Do not present injected MOTS-c as proven to:

• cause fat loss

• reverse insulin resistance

• treat diabetes

• improve endurance

• increase energy

• replace exercise

• prevent muscle loss

• treat GLP-1 fatigue

• extend lifespan

• reverse aging

• build new mitochondria in humans

• increase human fat burning after injection

Commonly Paired With

NAD+

Different role in cellular energy metabolism.

Classification: Could be complementary, but human combination evidence does not exist.

SS-31 / Elamipretide

Different mitochondrial mechanism.

Classification: Different pathways; combination untested.

L-Carnitine

Helps transport fatty acids into mitochondria.

Classification: Different mechanism; combination unproven.

GLP-1 Agonists

Different signaling pathways.

Classification: Different mechanisms, but no evidence MOTS-c prevents GLP- 1-related fatigue.

AICAR

Greater overlap with AMPK-related signaling.

Classification: More pathway overlap; combination untested.

Dosage Information

Native MOTS-c Human Trial

Phase: 2a Route: Subcutaneous T reatment: 12 weeks F ollow-up: Additional safety follow-up Population: Adults with prediabetes and overweight/obesity Estimated enrollment: About 120. ( clinicaltrials.gov) Important This is:

an experimental research regimen not:

an approved MOTS-c protocol

Human Clinical Research

No Results Timeline Y et The active study is evaluating metabolic outcomes after approximately:

12 weeks of treatment. ( clinicaltrials.gov) Until the results are published, Navaro should not say:

MOTS-c starts working by week 2.

Natural Human MOTS-c Research

Exercise can change the MOTS-c naturally present in the human body.

(pubmed.ncbi.nlm.nih.gov) That tells us something about MOTS-c biology.

It does not tell us how quickly an injection produces a treatment effect.

Community-Reported

Community sources describe subjective changes over:

several days to several weeks with many protocols lasting around:

4–6 weeks Evidence W arning Always label these:

Community-reported

not:

Expected clinical results

Regulatory Status

United States

FDA Approved?

No Neither MOTS-c free base nor MOTS-c acetate is part of an FDA-approved drug. ( fda.gov)

Human Trial Status

Phase 2a underway The active study is testing MOTS-c in adults with:

• prediabetes

• overweight or obesity. ( clinicaltrials.gov)

Compounding

FDA evaluated MOTS-c free base and MOTS-c acetate in 2026.

FDA staff concluded that the available evidence weighed:

against inclusion on the 503A Bulks List. ( fda.gov)

W ADA

Prohibited The 2026 W ADA Prohibited List specifically includes MOTS-c as an example of an AMPK activator. ( wada-ama.org)

What Studies Have Found

Foundational MOTS-c Research

The foundational research identified MOTS-c as a mitochondrial-derived peptide involved in metabolic regulation.

Animal and laboratory work found effects involving:

• metabolic homeostasis

• insulin resistance

• obesity-related metabolism

What This Supports

• MOTS-c is biologically active

• metabolic signaling is real

• AMPK-related mechanisms are plausible

What It Does Not Support

• a human 5 mg protocol

• human fat loss

• human endurance enhancement

• human anti-aging therapy

Human Exercise Research

Human research shows that:

natural MOTS-c increases with exercise. (pubmed.ncbi.nlm.nih.gov) What This Supports MOTS-c appears to participate in normal human exercise biology.

What It Does Not Support A clinically proven injection protocol:

• 30 minutes before exercise

• 60 minutes before exercise

• 90 minutes before exercise

MOTS-MET Phase 2a Trial

The current trial is:

NCT07505745 It is studying approximately:

120 adults with prediabetes and overweight or obesity.

The trial compares:

MOTS-c with:

placebo over approximately:

12 weeks with further safety follow-up. ( clinicaltrials.gov) Main Question Can MOTS-c improve:

insulin sensitivity?

Current Status Ongoing Results Not available yet

FDA 2026 Evaluation

FDA’s review is particularly useful for separating what we know from what peptide websites claim.

FDA reported that its literature search did not identify human administration studies that could establish MOTS-c’s effectiveness or safety and noted that the exact molecular targets remain unknown. ( fda.gov) What This Means for Navaro Do not describe these as established facts:

• proven human insulin-sensitivity improvement

• proven endurance improvement

• hypoglycemia as the major known side effect

• known human half-life

• standard 5 mg dosing

• mandatory pre-workout use

No FDA-Approved MOTS-c Product Exists

There is no approved reference product giving us one universal:

• vial strength

• mixing method

• diluent

• storage temperature after mixing

• expiration after reconstitution

FDA also reviewed free-base and acetate forms separately and identified significant characterization concerns. ( fda.gov)

Free Base vs Acetate

FDA considers:

• MOTS-c free base

• MOTS-c acetate

to be different bulk drug substances. ( fda.gov)

Simple V ersion Do not assume every vial labeled:

MOTS-c is chemically identical.

Community Research Vials

Community sources give their own instructions for:

• bacteriostatic water

• refrigeration

• use-after-mixing periods

Those instructions should be labeled:

Community handling practices not:

V alidated universal MOTS-c stability Simple Rule Do not apply one 14-day , 28-day or 30-day storage rule to every MOTS-c vial.

Dosing evidence

Dose at a Glance

Research-Community Dosing

Community protocols are very different from the clinical trial.

PeptideFox currently describes approximately:

5–10 mg per injection often:

2–3 times per week using SC or IM injections.

A commonly discussed starting amount is:

5 mg Evidence level Community / practitioner protocol These doses have not been established by completed human dose-finding trials of native MOTS-c.

FDA Compounding Nomination Doses

Another source of confusion is FDA’s compounding review.

The products submitted in the nomination included:

5 mg and:

10 mg

for SC injection. FDA explicitly describes these as proposed compounded products, not approved or validated doses. ( fda.gov) Important A dose being nominated to FDA does not mean:

FDA approved the dose.

In fact, FDA’s 2026 scientific review concluded that the evidence weighed against placing MOTS-c free base or MOTS-c acetate on the 503A Bulks List.

(fda.gov)

Frequency at a Glance

Timing at a Glance

Clinical

There is no established human evidence showing injected MOTS-c needs to be taken:

• before exercise

• after exercise

• in the morning

• at night

• fasted

• with food

The current live page should therefore not list:

Pre-W orkout as though it is a required dosing window.

Community

Community protocols often use MOTS-c:

• in the morning

• before cardio

• before endurance training

PeptideFox describes pre-exercise timing in its community material.

Why Did This Idea Develop?

The idea is understandable because the body’s own MOTS-c increases during exercise. ( pubmed.ncbi.nlm.nih.gov) But that does not prove an injection works better when taken before exercise.

Evidence verdict Pre-workout: Makes sense in theory, but unproven Morning: Community preference F asted: Unproven Required: No

Duration / Cycle at a Glance

Protocol Logic Check

Does Daily Dosing Make Sense?

Repeated SC treatment is now being tested in the Phase 2a trial.

That makes the clinical trial much more relevant than older community schedules. ( clinicaltrials.gov) But:

the trial has no results yet.

V erdict Currently being tested in humans

Does 2–3 Times Weekly Make Sense?

This is common in peptide communities.

But no completed human study shows that 2–3 times per week is the best schedule.

V erdict Community protocol

Does Once-Weekly Dosing Make Sense?

Some community protocols use once-weekly injections.

We do not have human research showing that one injection per week provides enough exposure for the proposed metabolic effects.

V erdict Community protocol / unproven

Does Pre-Workout Timing Make Sense?

There is a reason people came up with the idea.

Natural MOTS-c increases during human exercise. ( pubmed.ncbi.nlm.nih.gov) So pairing an experimental MOTS-c injection with exercise may sound logical.

But no human trial has shown that injections work better:

• 30 minutes before exercise

• 60 minutes before exercise

• 90 minutes before exercise

than at another time.

V erdict Makes sense in theory , but unproven

Does It Have to Be Used With Exercise?

No evidence says it does.

The live page’s:

“always dose pre-workout, never fasted without planned exercise” should be removed.

V erdict No demonstrated requirement

Does Fasted Dosing Make Sense?

Fasting activates many energy-sensing pathways.

That gives the idea some biological logic.

But no human injection study has shown that MOTS-c works better while fasted.

V erdict Possible in theory , but unproven

Morning or Evening?

We do not know.

Morning use is mostly a community preference, often because users combine MOTS-c with exercise.

V erdict Community preference

4–6 Weeks On / 2–4 Weeks Off

This is commonly discussed in community protocols.

But no human research shows that MOTS-c suddenly stops working after 4–6 weeks.

There is also no evidence showing that taking several weeks off restores sensitivity.

V erdict Community convention

Does It Need a Receptor Reset?

Probably not a useful way to think about MOTS-c.

We do not even have a clearly identified MOTS-c receptor.

So claims that:

“the MOTS-c receptor needs to reset” are especially weak.

V erdict No demonstrated receptor-reset mechanism

Does It Need a Washout?

There is no established:

• 2-week break

• 4-week break

• reset period

for MOTS-c.

V erdict No demonstrated requirement

Dose Escalation / Titration

The live page includes several very different protocols, including:

200 mcg → 1,000 mcg daily and other schedules using:

• 3 mg

• 5 mg

• 10 mg

at different intervals.

There is no completed human dose-ranging study showing that these ladders are correct.

V erdict These are different community protocols, not proven clinical titration schedules.

They should not be grouped under:

Standard Protocol

4. Community Injection Protocols

Community protocols use things such as:

• 5 mg

• 10 mg

• multiple injections per week

• pre-workout timing

• cycling

• stacking

These are worth documenting.

But they should be labeled:

Community protocols not:

Human clinical dosing

Common Research Dose

Research Duration / Cycle Length

Human Trial

12 weeks of treatment with additional safety follow-up. ( clinicaltrials.gov)

Community

Commonly:

4–6 weeks on followed by:

2–4 weeks off Evidence Assessment The clinical study duration is simply:

how the trial was designed.

The community cycle is:

a community convention.

Neither proves that MOTS-c biologically requires cycling.

How Often It Is Used / Frequency

Community Research Protocol

Community Pattern

PeptideFox currently describes approximately:

Dose: 5–10 mg Route: SC or IM F requency: commonly several times weekly

Timing: often morning / around exercise Cycle: commonly 4–6 weeks followed by a break Evidence Check SC route: Being studied in humans IM route: Community use 5–10 mg: Community dosing Several times weekly: Community dosing Pre-workout: Makes sense in theory but unproven Morning: Community preference 4–6 week cycle: Community convention 2–4 week break: No proven reset requirement

Current Live Navaro Protocol Review

The current live page contains several very different protocols.

Examples include:

• 5 mg weekly followed by twice weekly

• 10 mg weekly

• 200 mcg → 1 mg daily

• 5 mg every 5 days

• 3 mg every 3 days

Problem There is no human dose-ranging study showing that one of these is the:

standard MOTS-c protocol Recommendation Replace:

Standard Protocol with:

Community Protocol Examples Then put the current human Phase 2a research above the community protocols.

Community Protocol Comparison

Source Dose Route Frequency Duration Evidence Current Phase 2a Not established here SC Repeated treatment 12 weeks Ongoing human trial FDA nomination 5 / 10 mg proposed SC Proposed Not validated Compounding nomination PeptideF ox 5–10 mg SC / IM Several times weekly Short cycles Community Live examples Variable SC Variable Variable Community Strongest Agreement SC is currently the route with the strongest human-research precedent.

Biggest Unknown Dose and frequency We simply do not have completed human data establishing the best regimen.

Expected Results Timeline, Expanded

Contraindications

Safety at a Glance

Human Safety Profile

Not established yet MOTS-c does not currently have a completed human injection study that can give us a reliable table of:

• common side effects

• uncommon side effects

• serious adverse effects

• exact rates

FDA’s 2026 review specifically said there was not enough human administration information to determine the safety of MOTS-c and highlighted uncertainty around immunogenicity and product quality. ( fda.gov)

FDA Safety Concerns

FDA highlighted possible concerns involving:

• immune reactions to the peptide

• peptide clumping or aggregation

• impurities

• differences between products sold as MOTS-c

• manufacturing consistency

• inadequate characterization of the active ingredient

These concerns are particularly important for injected peptide products.

(fda.gov)

Major Contraindications

Formal FDA Contraindications

None established This is because MOTS-c is:

not an FDA-approved medication There is no approved product label containing an official contraindication list.

Navaro should therefore avoid turning theoretical concerns into formal contraindications.

Important Cautions

Pregnancy

Human fetal-safety information does not exist.

Classification: Safety unknown / avoid experimental exposure.

Breastfeeding

No adequate human safety data.

Classification: Unknown.

Children and Adolescents

No established injected-MOTS-c safety or effectiveness.

Classification: Unstudied.

Diabetes Medications

Because MOTS-c is being studied for insulin sensitivity, combining it with glucose-lowering medications could potentially change glucose control.

This may include:

• insulin

• sulfonylureas

• other glucose-lowering drugs

There is not yet a human interaction study telling us the size of that risk.

Classification: Important theoretical caution, not a proven contraindication.

Metformin

MOTS-c and metformin research both involve some of the same metabolic signaling pathways, including AMPK-related biology.

That does not prove the combination is dangerous.

Classification: Pathway overlap; actual interaction unknown.

Active Cancer

There are not enough human data to establish safety in people with active malignancy.

Classification: Unknown risk, not a formal contraindication.

FDA Safety Concerns

FDA highlighted uncertainty around:

• immune reactions

• peptide aggregation

• impurities

• active ingredient identity

• manufacturing quality. ( fda.gov)

Community-Reported Effects

Community material describes things such as:

• injection-site irritation

• fatigue

• temporary discomfort

• occasional stomach symptoms

Important These are:

anecdotal reports not:

established clinical adverse-effect rates

Contraindications & Cautions

Formal Contraindications

None established There is no FDA-approved MOTS-c medication and therefore no official productlabel contraindication list.

Important Cautions

Pregnancy / Breastfeeding No adequate human safety data.

Children / Adolescents No established injected-MOTS-c safety or efficacy.

Diabetes / Glucose-Lowering Drugs An interaction is biologically possible because MOTS-c is being studied for metabolic effects.

Actual human interaction risk is unknown.

Active Cancer Human safety is unknown.

Serious Cardiovascular Disease Human injection safety is not established.

Immune Reactions FDA specifically identified immunogenicity as an area of concern with injectable compounded MOTS-c products. ( fda.gov)

Side effects

Reported Side Effects

Controlled Human Injection Data

Not established yet We do not currently have a completed native-MOTS-c treatment trial that gives reliable side-effect percentages.

Compatibility

Stack / Pairing Logic

MOTS-c + NAD+

They affect different parts of cellular energy metabolism.

V erdict: Could be complementary, but no controlled human combination trial exists.

MOTS-c + SS-31 / Elamipretide

SS-31 works mainly through mitochondrial membrane and cardiolipin biology.

MOTS-c works through metabolic signaling.

V erdict: Different mechanisms, but the combination is untested.

MOTS-c + L-Carnitine

L-Carnitine helps fatty acids get into mitochondria.

MOTS-c appears to influence metabolic signaling.

V erdict: Different mechanisms and theoretically complementary, but clinically unproven.

MOTS-c + GLP-1 Drugs

The mechanisms are different.

MOTS-c is sometimes promoted as a way to reduce fatigue during GLP-1 treatment.

There is no controlled human evidence showing that it prevents or treats GLP-1-related fatigue.

V erdict: Different mechanisms, but claimed benefit is unproven.

MOTS-c + AICAR

Both involve AMPK-related metabolic signaling.

V erdict: Greater pathway overlap; combination untested.

Source url

Research Sources

1. Lee et al. 2015: F oundational MOTS-c Research Evidence type: Foundational preclinical research Supports:

• 16-amino-acid mitochondrial-derived peptide

• mitochondrial DNA origin

• metabolic signaling

• animal insulin-resistance and obesity findings

• AMPK-related pathway

https://pubmed.ncbi.nlm.nih.gov/25738459/

2. Reynolds et al. 2021: MOTS-c and Exercise Evidence type: Human physiological + animal experimental research Supports:

• exercise-related endogenous MOTS-c changes in humans

• human muscle and circulating MOTS-c response

• animal physical-capacity research

Does not establish injected-human treatment efficacy.

https://pubmed.ncbi.nlm.nih.gov/33473109/ 3. von W alden et al. 2021: Acute Endurance Exercise Evidence type: Human physiological research Supports:

• acute endurance exercise changes circulating mitochondrial-derived pep-

tides Does not establish a pre-workout MOTS-c injection protocol.

https://pubmed.ncbi.nlm.nih.gov/34351816/ 4. ClinicalT rials.gov: MOTS-MET Phase 2a Evidence type: Active human clinical trial Supports:

• Phase 2a human research

• adults with prediabetes and overweight/obesity

• SC administration

• 12-week treatment

• insulin-sensitivity research

• human safety monitoring

https://clinicaltrials.gov/study/NCT07505745 5. FDA 2026 MOTS-c 503A Evaluation Evidence type: FDA scientific and regulatory review Supports:

• no FDA-approved MOTS-c drug

• lack of established human administration evidence in FDA’s review

• unknown human safety

• insufficient effectiveness evidence

• immunogenicity concerns

• free-base vs acetate concerns

• FDA staff conclusion against 503A inclusion

https://www.fda.gov/media/193347/download 6. FDA: Bulk Drug Substances That May Present Significant Safety Risks Evidence type: FDA safety and regulatory information Supports:

• immunogenicity concerns

• peptide impurity concerns

• active-ingredient characterization concerns

• lack of adequate human safety information

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks 7. FDA: July 2026 Pharmacy Compounding Advisory Committee Evidence type: Regulatory-process source Supports:

• 2026 review of MOTS-c free base and acetate

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 8. W ADA 2026 Prohibited List Evidence type: Anti-doping regulation Supports:

• MOTS-c listed as an AMPK activator

• prohibited status under W ADA rules. ( wada-ama.org)

https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

9. PeptideF ox: MOTS-c Evidence type: Community / practitioner protocol Useful for documenting:

• community dosing

• multiple weekly injections

• SC / IM use

• exercise timing

• cycling

• anecdotal timelines

• community handling practices

It should not override FDA, ClinicalTrials.gov or controlled human evidence.

https://peptidefox.com/content/mots-c

Final Takeaway

MOTS-c has interesting science behind it, but human injection evidence is still very early .

What we know:

• MOTS-c is a real 16-amino-acid mitochondrial-derived peptide

• its genetic instructions come from mitochondrial DNA

• it participates in metabolic signaling

• natural human MOTS-c changes with exercise

• animal studies show important metabolic effects

• a human Phase 2a treatment trial is now underway. ( fda.gov)

What we still do not know:

• the best human dose

• the best frequency

• the best injection timing

• its injected-human half-life

• whether it actually improves insulin sensitivity

• whether it causes fat loss

• whether it improves endurance

• whether it improves fatigue

• its true human side-effect rates

• whether cycling provides any benefit

Community protocols commonly use approximately:

5–10 mg

several times per week, often around exercise.

Those belong under:

Community Protocols not:

Clinical Dosing The biggest live-page fixes remain:

Do not call AMPK the MOTS-c receptor. The exact target is still unknown.

Do not require pre-workout dosing.

Do not describe low blood sugar as the established major MOTS-c side effect. Human injection safety data are not available yet.

Do not label one community schedule the “Standard Protocol. ” Put the active Phase 2a human trial above the community dosing section.

Keep MOTS-c clearly labeled as not FDA approved and W ADA prohibited. (fda.gov)

Navaro Compounds.pdf, pages 123–169.

Storage

Formulation / Stability / Sterility Logic

This area deserves extra caution.

FDA identified concerns involving:

• impurities

• peptide aggregation

• immune reactions

• product identity

• bacterial endotoxins

• differences between free-base and acetate products. ( fda.gov)

Simple V ersion Not every vial labeled:

“MOTS-c” can automatically be assumed to contain the exact same pharmaceutical substance.

And there is no universal rule saying:

Mix MOTS-c with bacteriostatic water and use it for 28 days.

V erdict Storage and handling need evidence for the exact formulation.

Formulation / Stability / Sterility

Supplied Navaro reference

Research Sources

1. Lee et al. 2015: F oundational MOTS-c Research Evidence type: Foundational preclinical research Supports:

• 16-amino-acid mitochondrial-derived peptide

• mitochondrial DNA origin

• metabolic signaling

• animal insulin-resistance and obesity findings

• AMPK-related pathway

https://pubmed.ncbi.nlm.nih.gov/25738459/

2. Reynolds et al. 2021: MOTS-c and Exercise Evidence type: Human physiological + animal experimental research Supports:

• exercise-related endogenous MOTS-c changes in humans

• human muscle and circulating MOTS-c response

• animal physical-capacity research

Does not establish injected-human treatment efficacy.

https://pubmed.ncbi.nlm.nih.gov/33473109/ 3. von W alden et al. 2021: Acute Endurance Exercise Evidence type: Human physiological research Supports:

• acute endurance exercise changes circulating mitochondrial-derived pep-

tides Does not establish a pre-workout MOTS-c injection protocol.

https://pubmed.ncbi.nlm.nih.gov/34351816/ 4. ClinicalT rials.gov: MOTS-MET Phase 2a Evidence type: Active human clinical trial Supports:

• Phase 2a human research

• adults with prediabetes and overweight/obesity

• SC administration

• 12-week treatment

• insulin-sensitivity research

• human safety monitoring

https://clinicaltrials.gov/study/NCT07505745 5. FDA 2026 MOTS-c 503A Evaluation Evidence type: FDA scientific and regulatory review Supports:

• no FDA-approved MOTS-c drug

• lack of established human administration evidence in FDA’s review

• unknown human safety

• insufficient effectiveness evidence

• immunogenicity concerns

• free-base vs acetate concerns

• FDA staff conclusion against 503A inclusion

https://www.fda.gov/media/193347/download 6. FDA: Bulk Drug Substances That May Present Significant Safety Risks Evidence type: FDA safety and regulatory information Supports:

• immunogenicity concerns

• peptide impurity concerns

• active-ingredient characterization concerns

• lack of adequate human safety information

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks 7. FDA: July 2026 Pharmacy Compounding Advisory Committee Evidence type: Regulatory-process source Supports:

• 2026 review of MOTS-c free base and acetate

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 8. W ADA 2026 Prohibited List Evidence type: Anti-doping regulation Supports:

• MOTS-c listed as an AMPK activator

• prohibited status under W ADA rules. ( wada-ama.org)

https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

9. PeptideF ox: MOTS-c Evidence type: Community / practitioner protocol Useful for documenting:

• community dosing

• multiple weekly injections

• SC / IM use

• exercise timing

• cycling

• anecdotal timelines

• community handling practices

It should not override FDA, ClinicalTrials.gov or controlled human evidence.

https://peptidefox.com/content/mots-c

Final Takeaway

MOTS-c has interesting science behind it, but human injection evidence is still very early .

What we know:

• MOTS-c is a real 16-amino-acid mitochondrial-derived peptide

• its genetic instructions come from mitochondrial DNA

• it participates in metabolic signaling

• natural human MOTS-c changes with exercise

• animal studies show important metabolic effects

• a human Phase 2a treatment trial is now underway. ( fda.gov)

What we still do not know:

• the best human dose

• the best frequency

• the best injection timing

• its injected-human half-life

• whether it actually improves insulin sensitivity

• whether it causes fat loss

• whether it improves endurance

• whether it improves fatigue

• its true human side-effect rates

• whether cycling provides any benefit

Community protocols commonly use approximately:

5–10 mg

several times per week, often around exercise.

Those belong under:

Community Protocols not:

Clinical Dosing The biggest live-page fixes remain:

Do not call AMPK the MOTS-c receptor. The exact target is still unknown.

Do not require pre-workout dosing.

Do not describe low blood sugar as the established major MOTS-c side effect. Human injection safety data are not available yet.

Do not label one community schedule the “Standard Protocol. ” Put the active Phase 2a human trial above the community dosing section.

Keep MOTS-c clearly labeled as not FDA approved and W ADA prohibited. (fda.gov)

Navaro Compounds.pdf, pages 123–169.